NCT06243198View on ClinicalTrials.gov

A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

September 3, 2024

Study Completion Date

September 3, 2024

Conditions

Healthy

Interventions

DRUG

Lebrikizumab

Administered subcutaneously (SC)

DRUG

Placebo

Administered subcutaneously (SC)

Trial Locations (1)

Unknown

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06243198 - A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants | Biotech Hunter | Biotech Hunter